NCT05112601 2026-03-18
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
4 trialsNCT03367741 2025-07-28
Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05795244 2025-05-13
Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)
Yonsei University
Phase 2 Recruiting
NCT03241745 2024-12-27
A Study of Nivolumab in Selected Uterine Cancer Patients
Memorial Sloan Kettering Cancer Center
Phase 2 Completed